Lifesciences: Select Prior
 | Vascular Pathways Markets its patented FDA-cleared rapid intravascular start device for placing peripheral intravenous catheters | Acquired by C.R.Bard | |
 | Mevion Developing high quality, cost-effective proton therapy solutions | Acquired privately | |
 | Valeritas Disposable insulin pump for Type 2 diabetics | IPO | |
 | OpGen Develops novel molecular diagnostics with broad applications in infectious disease | IPO | |
 | Resolvyx Pharmaceuticals Novel anti-inflammatory agents based on endogenous mediators of inflammation resolution | Acquired privately | |
 | Vaxinnate Vaccine development | Acquired privately | |
 | Oriel Therapeutics Novel drug delivery devices for the respiratory drug market | Acquired by Sandoz/Novartis | |
 | Bikam Novel small molecule therapeutics for ophthalmic diseases | Acquired by Shire Pharmaceuticals | |
 | Threshold Pharmaceuticals Therapeutics that target hypoxic cells to treat cancer and benign prostatic hyperplasia | IPO | |
 | Amicus Therapeutics Small molecule therapeutics for genetic disorders | IPO | |
 | GeneOhm Sciences Developer of chip-based instruments and reagents for molecular diagnostics | Acquired by Becton Dickinson | |
 | LuMend Catheter-based devices to treat occluded arteries | Acquired by Johnson & Johnson | |
 | Protometrix Development and manufacture of protein microarrays | Acquired by Invitrogen Corporation | |
 | Genomic Health Consumer focused applied genomics |
IPO; Acquired by Exact Sciences | |
 | Durect Drug delivery technology for localized treatment of disease | IPO | |
 | Cellular Genetics Cellular and proteomics approaches to target validation for drug development | Acquired by Gilead | |
 | Molecular Staging Novel technologies for immunodiagnostics | Acquired by QIAGEN N.V. | |
 | Revivant Devices to assist in the resuscitation of victims of sudden cardiac arrest | Acquired by Zoll Medical Corporation | |
 | Alexion Pharmaceuticals Complement inhibition for cardiovascular and inflammatory diseases | IPO | |
 | GelTex Pharmaceuticals Non-absorbed pharmaceuticals to emilinate target substances from the gastrointestinal tract | IPO; Acquired by Genzyme Corporation | |
 | Neurocrine Biosciences Therapeutics for diseases and disorders of the central nervous and immune systems | IPO | |
 | CV Therapeutics Prevention and treatment of cardiovascular disease | IPO; Acquired by GILEAD | |
 | Incyte Provider of a leading integrated platform of genomic technologies and services | IPO | |
 | Icos Chronic inflammatory disease therapeutics | IPO | |
 | Celgene Discovery and development of small molecules for cancer and immunological diseases | IPO | |